
ePT--the Electronic Newsletter of Pharmaceutical Technology
FDA Approves Flu Vaccines; Caraco Names COO; And More.

ePT--the Electronic Newsletter of Pharmaceutical Technology
FDA Approves Flu Vaccines; Caraco Names COO; And More.

ePT--the Electronic Newsletter of Pharmaceutical Technology
Legislative efforts to modernize provisions in the Toxic Substances Control Act of 1976 (TSCA), which involve chemical safety and reporting requirements is drawing criticism from the chemical industry.

Industry's focus on cost cutting has led to a dangerous gap in training and knowledge.

Manufacturers and regulators on both sides of the ocean move to ensure the safety of heparin and other globally distributed drug products.

Chemocatalytic and biocatalytic approaches in asymmetric synthesis help provide a pathway for producing single-enantiomer drugs.

Green chemistry in pharmaceutical development often centers around approaches in the synthesis of the active ingredient, but green-chemistry techniques also can be applied to drug-product manufacturing, formulation development, and drug delivery.

As emerging markets become increasingly important for the pharmaceutical majors, companies are re-evaluating their outsourcing strategies. This article is part of the 2010 Outsourcing Resources special issue.

ePT--the Electronic Newsletter of Pharmaceutical Technology
Merck and Sinopharm Sign Agreement; Agilent Appoints CFO; And More.

ePT--the Electronic Newsletter of Pharmaceutical Technology
Pfizer Ends Second Tanezumab Clinical Program; Catalent VP Joins USP Panel; And More.

ePT--the Electronic Newsletter of Pharmaceutical Technology
The Society of Chemical Manufacturers and Affiliates (SOCMA) expressed "strong concern" over legislation introduced in the US Senate earlier this month regarding chemical-site security.

ePT--the Electronic Newsletter of Pharmaceutical Technology
Merck KGaA (Darmstadt, Germany), a global pharmaceutical and chemical company, completed its acquisition of Millipore (Billerica, MA), a life-science company, last Thursday for an aggregate purchase price of roughly EUR 5.2 billion ($6.7 billion).

ePT--the Electronic Newsletter of Pharmaceutical Technology
Xcelience and Penn Form Joint Venture; Almac Appoints QA Director; And More.

ePT--the Electronic Newsletter of Pharmaceutical Technology
The US House of Representatives passed on July 1, 2010, HR 4899, the Supplemental Appropriations Act of 2010, which included provisions restricting patent settlements between innovator-drug and generic-drug companies, a move that drew criticism from both sectors of the pharmaceutical industry.

ePT--the Electronic Newsletter of Pharmaceutical Technology
Eli Lilly to Acquire Alnara Pharmaceuticals; Exelixis CEO Leaves for Biogen Idec; And More.

As generic divisions become the most-wanted acquisitions of Big Pharma, India's domestic industry may be thinning out.

The functionality and performance of three types of commercial superdisintegrants were evaluated in the application of orally disintegrating tablets.

Technical Note: The authors investigated the variables important for calcium-alginate formation as well as dissolution.

Excipient manufacturers expand their products, services, manufacturing capacity, and technology positions.

After a spate of industrial disasters, the public seeks greater oversight of corporations-so does FDA.

ePT--the Electronic Newsletter of Pharmaceutical Technology
Pfizer Suspends Tanezumab Program; Actavis Appoints CEO; And More.

Pharmaceutical Technology Europe
How can crystal engineering and pharma sciences be combined to enhance the clinical performance of drugs?

ePT--the Electronic Newsletter of Pharmaceutical Technology
Company and People Notes: Valeant and Biovail to Merge; GPhA Names Interim Director; And More.

ePT--the Electronic Newsletter of Pharmaceutical Technology
GSK Acquires Laboratorios Phoenix; Catalent Makes Executive Appointments; And More.

ePT--the Electronic Newsletter of Pharmaceutical Technology
Thermo Fisher to Acquire Fermentas; Pfizer Names Head of R&D; And More.

Europe moves to place excipient GMP and GDP standards on the same level as active pharmaceutical ingredients.